Want to see AU:LGP full AI Analyst Report?
LGP Stock Chart & Stats
AU$0.10
<AU$0.01(1.67%)
At close: 4:00 PM EST
AU$0.10
<AU$0.01(1.67%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.15
Previous CloseN/A
Volume21.69K
Average Volume (3M)234.87K
Market Cap
AU$62.62M
Enterprise ValueAU$28.30M
Total Cash (Recent Filing)AU$1.42M
Total Debt (Recent Filing)AU$4.69M
Price to Earnings (P/E)―
Beta0.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding823,978,700
10 Day Avg. Volume223,605
30 Day Avg. Volume234,865
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.36
Price to Sales (P/S)0.70
P/FCF Ratio-37.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside50.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetLow reported debt (~A$4.7m versus equity ~A$83.0m) gives LGP financial flexibility to absorb regulatory or market setbacks, fund targeted capex or working capital, and support measured international expansion without immediate refinancing. This conservatism supports multi-quarter operational resilience and strategic optionality.
Sustained Revenue Scaling Over YearsScaling revenue from low single digits to ~A$42m over several years indicates durable market traction, growing distribution reach and product acceptance in regulated channels. That scale can enable manufacturing efficiencies, stronger distributor relationships, and room to improve unit economics over multiple quarters.
Improving Operating Cash GenerationOperating cash flow moving to roughly breakeven in 2026 after prior negatives signals operational improvements and better working capital control. If sustained, this reduces reliance on external funding, supports incremental reinvestment in production or quality systems, and strengthens the path to positive free cash flow.
Bears Say
Recent Revenue Decline And Negative Operating ProfitAn 11.9% revenue decline in 2026 alongside a return to net loss and negative EBIT highlights demand or pricing pressure and operating volatility. This undermines predictability for reinvestment and suggests the core business has not yet achieved consistently sustainable operating profitability across market cycles.
Negative Free Cash Flow PersistsDespite improvements, persistent negative free cash flow (~-A$0.79m in 2026) means the business still consumes external capital to fund operations or growth. Ongoing negative FCF constrains strategic flexibility, raises funding risk, and could limit the company’s ability to invest in capacity or new market entry without new financing.
Uneven Returns On Shareholder CapitalA sizeable asset and equity base paired with inconsistent profitability implies weak conversion of capital into returns. That uneven ROIC suggests potential inefficiencies in capital allocation, margin pressure, or execution gaps that, if unaddressed, risk long‑term shareholder value creation and could necessitate restructuring of investments.
Little Green Pharma Ltd. News
LGP FAQ
What was Little Green Pharma Ltd.’s price range in the past 12 months?
Little Green Pharma Ltd. lowest share price was AU$0.06 and its highest was AU$0.14 in the past 12 months.
What is Little Green Pharma Ltd.’s market cap?
Little Green Pharma Ltd.’s market cap is AU$62.62M.
When is Little Green Pharma Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Little Green Pharma Ltd.’s earnings last quarter?
Currently, no data Available
Is Little Green Pharma Ltd. overvalued?
According to Wall Street analysts Little Green Pharma Ltd.’s price is currently Undervalued.
Does Little Green Pharma Ltd. pay dividends?
Little Green Pharma Ltd. does not currently pay dividends.
What is Little Green Pharma Ltd.’s EPS estimate?
Little Green Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Little Green Pharma Ltd. have?
Little Green Pharma Ltd. has 823,978,700 shares outstanding.
What happened to Little Green Pharma Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Little Green Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:LGP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Little Green Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.15 (50.00% Upside)
AU$0.15 (50.00% Upside)
Blogger Sentiment
Bullish
AU:LGP Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.46%
Trailing 12-Months
Company Description
Little Green Pharma Ltd.
Little Green Pharma Ltd, established in 2016 and based in West Perth, Australia, specializes in the worldwide cultivation, manufacturing, and distribution of medicinal cannabis products. Its extensive product range encompasses cannabis flower medicines, various cannabis extracts, tinctures, and active pharmaceutical ingredients (APIs), serving markets both within Australia and internationally.
LGP Stock 12 Month Forecast
Average Price Target
AU$0.15
▲(50.00% Upside)
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―